Results 261 to 270 of about 161,983 (298)

Magnesium and Cancer Immunotherapy: A Narrative Practical Review. [PDF]

Nutrients
Sambataro D, Scandurra G, Gebbia V, Greco M, Ciminna A, Valerio MR.   +5 more
europepmc   +1 more source

Voices: Future directions in targeting the tumor microenvironment. [PDF]

Cell Rep Med
de Gruijl T, Sautès-Fridman C, Thommen DS, Curran MA.   +3 more
europepmc   +1 more source

Commentary: Correlation between different levels of thyroid autoantibodies and immune checkpoint inhibitor-associated thyroid dysfunction. [PDF]

Front Endocrinol (Lausanne)
Zhang D, Jing R, Chen Z, Zhang P, Cai M.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Clinical toxicology of immune checkpoint blockers

Toxicology Letters, 2021
N. Chaput
semanticscholar   +2 more sources

Initial development of biosimilar immune checkpoint blockers using HEK293 cells

Protein Expression and Purification, 2020
Antibodies that block interaction of immune checkpoint receptors with its ligands have revolutionized the treatment of several cancers. Despite the success of this approach, the high cost has been restricted the use of this class of drugs. In this context, the development of biosimilar can be an important strategy for reducing prices and expanding ...
Michael Bernardes, Ramos, Anna Erika Vieira de, Araújo, Cristiane Pinheiro, Pestana, Ana Paula Dinis, Ano Bom, Renata Chagas, Bastos, Aline, de Almeida Oliveira, Patrícia Cristina, da Costa Neves, Haroldo Cid, da Silva Junior   +7 more
openaire   +2 more sources

Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer.

Immunotherapy, 2021
Cancer initiation and progression are associated with immune system responses. Tumor cells use various tricks to scape of immune system, such as activating immune checkpoint pathways that induce immunosuppressive functions.
Mobina Jalalvand, Farzaneh Darbeheshti, N. Rezaei   +2 more
semanticscholar   +1 more source

Nanotechnology-based platforms to improve immune checkpoint blockade efficacy in cancer therapy.

Future Oncology, 2020
In recent years, cancer immunotherapy has evolved as an exciting novel strategy for researchers and clinicians worldwide. Immunotherapeutic agents such as immune checkpoint blockers have changed the standard-of-care treatment provided for many tumors ...
Deeksha G Lahori, P. Varamini
semanticscholar   +1 more source

Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma

2022
AbstractImmune checkpoint blockers (ICBs) have failed in all Phase III glioblastoma trials. Here, we found that ICBs induce cerebral edema in some patients and mice with glioblastoma. Through single-cell RNA sequencing, intravital imaging, and T cell blocking studies in mice, we demonstrated that this edema results from an inflammatory response ...
Meenal Datta, Sampurna Chatterjee, Elizabeth M. Perez, Simon Gritsch, Sylvie Roberge, Mark Duquette, Ivy X. Chen, Kamila Naxerova, Ashwin S. Kumar, Mitrajit Ghosh, Kyrre E. Emblem, Mei R. Ng, William W. Ho, Pragya Kumar, Shanmugarajan Krishnan, Xinyue Dong, Maria C. Speranza, Martha R. Neagu, David A. Reardon, Arlene H. Sharpe, Gordon J. Freeman, Mario L. Suvà, Lei Xu, Rakesh K. Jain   +23 more
openaire   +1 more source

Immune checkpoint blockade opens a new way to cancer immunotherapy

Journal of Cellular Physiology, 2018
Among the main promising systems to triggering therapeutic antitumor immunity is the blockade of immune checkpoints. Immune checkpoint pathways regulate the control and eradication of infections, malignancies, and resistance against a host of ...
Sanam Sadreddini, B. Baradaran, Ali Aghebati-Maleki, S. Sadreddini, D. Shanehbandi, A. Fotouhi, L. Aghebati-Maleki   +6 more
semanticscholar   +1 more source

New Clinical Approaches and Emerging Evidence on Immune-Checkpoint Inhibitors as Anti-Cancer Therapeutics: CTLA-4 and PD-1 Pathways and Beyond.

Critical Reviews in Immunology, 2019
Background-The development of immune checkpoint blockers, primarily comprising the anti-PD-1/an-ti-PD-L1 and anti-CTLA-4 monoclonal antibodies, has formed the therapeutic landscape of quite a few different cancer types.
M. Christodoulou, A. Zaravinos
semanticscholar   +1 more source